Aeglea BioTherapeutics, Inc. (AGLE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 6.68B |
| Enterprise Value | 6.59B |
| P/E Ratio | -54.61 |
| PEG Ratio | 1.07 |
| Price/Sales Ratio | 102.19 |
| Price/Book Ratio | 8.19 |
| Enterprise/Revenue | 100.4 |
| Enterprise/EBITDA | -48.97 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
| Profit Margin | -1.98 |
| Operating Margin | -2.22 |
| Return On Assets | -0.15 |
| Return On Equity | -0.24 |
| Revenue | 0 |
| Revenue/Share | 1.07 |
| Gross Profit | 0 |
| EBITDA | -155.22M |
| Net Income | -155.2M |
| Diluted EPS | -1.98 |
| Total Cash | 1.15B |
| Total Cash/Share | 13.52 |
| Total Debt | 0 |
| Total Debt/Equity | 0 |
| Current Ratio | 18.53 |
| Book Value Per Share | 13 |
| 52-Week Change | 23.81 |
| 52-Week High | 24 |
| 52-Week Low | 2.66 |
| Moving Average 50 Days | 12.64 |
| Moving Average 200 Days | 9.84 |
| Average Volume | 59,537 |
| Shares Outstanding | 4.05M |
| % Held by Institutions | 0.2 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:25 |
| Last Split Date | September 08, 2023 |